These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26068566)

  • 61. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
    Dresen S; Ferreirós N; Pütz M; Westphal F; Zimmermann R; Auwärter V
    J Mass Spectrom; 2010 Oct; 45(10):1186-94. PubMed ID: 20857386
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.
    Spiller HA; Ryan ML; Weston RG; Jansen J
    Clin Toxicol (Phila); 2011 Jul; 49(6):499-505. PubMed ID: 21824061
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Age, period, and cohort effects in synthetic cannabinoid use among US adolescents, 2011-2015.
    Keyes KM; Rutherford C; Hamilton A; Palamar JJ
    Drug Alcohol Depend; 2016 Sep; 166():159-67. PubMed ID: 27491817
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reports of adverse health effects related to synthetic cannabinoid use in New York State.
    Papadopoulos EA; Cummings KR; Marraffa JM; Aldous KM; Li L; Ahmad N
    Am J Addict; 2017 Dec; 26(8):772-775. PubMed ID: 29105968
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Psychoactive substances--some new, some old: a scan of the situation in the U.S.
    Maxwell JC
    Drug Alcohol Depend; 2014 Jan; 134():71-77. PubMed ID: 24140401
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Death after use of the synthetic cannabinoid 5F-AMB.
    Shanks KG; Behonick GS
    Forensic Sci Int; 2016 May; 262():e21-4. PubMed ID: 27017174
    [TBL] [Abstract][Full Text] [Related]  

  • 67. New Zealand bans synthetic cannabinoids.
    Brown K
    BMJ; 2011 Aug; 343():d5395. PubMed ID: 21862549
    [No Abstract]   [Full Text] [Related]  

  • 68. Retrospective analysis of synthetic cannabinoids in serum samples--epidemiology and consumption patterns.
    Jaenicke NJ; Pogoda W; Paulke A; Wunder C; Toennes SW
    Forensic Sci Int; 2014 Sep; 242():81-87. PubMed ID: 25050839
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A survey study to characterize use of Spice products (synthetic cannabinoids).
    Vandrey R; Dunn KE; Fry JA; Girling ER
    Drug Alcohol Depend; 2012 Jan; 120(1-3):238-41. PubMed ID: 21835562
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.
    Alves VL; Gonçalves JL; Aguiar J; Teixeira HM; Câmara JS
    Crit Rev Toxicol; 2020 May; 50(5):359-382. PubMed ID: 32530350
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States.
    Wang GS; Roosevelt G; Le Lait MC; Martinez EM; Bucher-Bartelson B; Bronstein AC; Heard K
    Ann Emerg Med; 2014 Jun; 63(6):684-9. PubMed ID: 24507243
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synthetic cannabinoids and potential reproductive consequences.
    Sun X; Dey SK
    Life Sci; 2014 Feb; 97(1):72-7. PubMed ID: 23827241
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
    Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
    J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Some new psychoactive substances: precursor chemicals and synthesis-driven end-products.
    Collins M
    Drug Test Anal; 2011; 3(7-8):404-16. PubMed ID: 21755608
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Medication errors reported to U.S. Poison Control Centers, 2000-2012.
    Brophy TJ; Spiller HA; Casavant MJ; Chounthirath T; Smith MD; Xiang H
    Clin Toxicol (Phila); 2014; 52(8):880-8. PubMed ID: 25175900
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA.
    Schwartz MD; Trecki J; Edison LA; Steck AR; Arnold JK; Gerona RR
    J Emerg Med; 2015 May; 48(5):573-80. PubMed ID: 25726258
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthetic cannabinoid drug use as a cause or contributory cause of death.
    Labay LM; Caruso JL; Gilson TP; Phipps RJ; Knight LD; Lemos NP; McIntyre IM; Stoppacher R; Tormos LM; Wiens AL; Williams E; Logan BK
    Forensic Sci Int; 2016 Mar; 260():31-39. PubMed ID: 26795398
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Feb; 62(6):93-8. PubMed ID: 23407124
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Analysis of intoxication with novel psychoactive substance (NPS) in Pomeranian region, from January to July 2015].
    Kabata P; Schetz D; Waldman W; Wiergowsk M; Sein Anand J
    Przegl Lek; 2015; 72(10):517-21. PubMed ID: 26946558
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Pharmacological properties and dependence liabilities of synthetic cannabinoids].
    Funada M
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Jun; 45(3):167-74. PubMed ID: 20681249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.